LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
LXRX on Nasdaq
Shares outstanding
363,214,619
Price per share
$1.15
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
255,139,258
Total reported value
$344,428,817
% of total 13F portfolios
0%
Share change
-1,196,786
Value change
-$1,111,792
Number of holders
121
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 10% +9% $26,696,274 +$2,516,037 38,137,535 +10% FMR LLC 30 Jun 2025

As of 30 Sep 2025, 121 institutional investors reported holding 255,139,258 shares of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX). This represents 70% of the company’s total 363,214,619 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Artal Group S.A. 37% 136,180,481 0% 24% $183,843,649
Siren, L.L.C. 11% 38,918,903 0% 2.1% $52,540,519
FMR LLC 11% 38,679,748 +1.4% 0% $52,217,659
VANGUARD GROUP INC 2.6% 9,521,874 +7.6% 0% $12,854,530
MILLENNIUM MANAGEMENT LLC 1.1% 3,830,660 +133% 0% $5,171,391
BlackRock, Inc. 0.93% 3,394,972 +1.2% 0% $4,583,212
Sessa Capital IM, L.P. 0.83% 3,000,000 0% 0.1% $4,050,000
CITADEL ADVISORS LLC 0.73% 2,634,027 0% $3,555,936
CIBC Private Wealth Group LLC 0.66% 2,400,257 -2% 0.01% $3,240,347
GEODE CAPITAL MANAGEMENT, LLC 0.66% 2,397,923 +0.85% 0% $3,238,240
GSA CAPITAL PARTNERS LLP 0.33% 1,202,906 -58% 0.14% $1,624,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.32% 1,144,632 +30% 0% $1,545,253
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.26% 962,060 +27% 0% $1,298,781
STATE STREET CORP 0.24% 880,121 +7.5% 0% $1,188,163
Schonfeld Strategic Advisors LLC 0.23% 825,633 -82% 0.01% $1,114,603
Hennion & Walsh Asset Management, Inc. 0.21% 779,212 -1.8% 0.04% $1,051,936
ROYAL BANK OF CANADA 0.2% 722,183 -6.7% 0% $975,000
JACOBS LEVY EQUITY MANAGEMENT, INC 0.19% 692,727 0% $935,181
TWO SIGMA INVESTMENTS, LP 0.15% 559,008 +38% 0% $754,661
Invesco Ltd. 0.14% 521,403 +24% 0% $703,894
JANE STREET GROUP, LLC 0.13% 456,530 -43% 0% $616,315
Compagnie Lombard Odier SCmA 0.11% 410,000 +24% 0.01% $553,500
NORTHERN TRUST CORP 0.1% 369,794 -11% 0% $499,222
UBS Group AG 0.1% 352,922 -12% 0% $476,445
Monaco Asset Management SAM 0.1% 350,000 -34% 0.18% $472,500

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,382,042 $1,589,214 +$119,162 $1.15 9
2025 Q3 255,139,258 $344,428,817 -$1,111,792 $1.35 121
2025 Q2 256,310,843 $242,983,204 -$6,845,383 $0.95 121
2025 Q1 265,818,368 $122,485,430 -$18,132,306 $0.46 124
2024 Q4 297,662,439 $220,126,714 -$8,084,075 $0.74 124
2024 Q3 288,616,985 $453,067,592 -$48,604,221 $1.57 134
2024 Q2 278,343,151 $467,625,172 +$175,856,984 $1.68 121
2024 Q1 171,815,966 $412,351,239 -$24,970,122 $2.40 114
2023 Q4 182,858,180 $279,771,925 -$6,759,847 $1.53 103
2023 Q3 188,793,708 $205,786,015 -$5,677,228 $1.09 109
2023 Q2 191,326,157 $438,152,499 +$104,558,326 $2.29 121
2023 Q1 145,600,839 $353,808,486 -$2,997,119 $2.43 102
2022 Q4 146,885,188 $280,547,551 -$3,977,447 $1.91 100
2022 Q3 148,905,062 $357,360,311 +$72,603,615 $2.40 98
2022 Q2 118,779,098 $220,940,693 -$2,430,736 $1.86 82
2022 Q1 120,193,264 $251,304,091 -$5,565,361 $2.09 100
2021 Q4 121,559,642 $478,894,149 -$1,466,109 $3.94 108
2021 Q3 121,205,281 $583,005,732 +$17,343,707 $4.81 96
2021 Q2 117,708,489 $540,207,653 +$2,119,118 $4.59 105
2021 Q1 121,214,904 $711,532,085 +$117,190 $5.87 103
2020 Q4 122,029,255 $417,334,864 +$65,690,726 $3.42 100
2020 Q3 104,248,250 $150,106,719 -$5,093,677 $1.44 83
2020 Q2 107,177,053 $213,813,923 +$4,797,305 $1.99 99
2020 Q1 104,815,254 $204,388,139 -$17,170,082 $1.95 107
2019 Q4 107,178,320 $444,778,336 +$20,431,577 $4.15 110
2019 Q3 102,423,092 $308,322,526 -$29,982,037 $3.01 95
2019 Q2 105,227,688 $661,832,362 +$7,044,227 $6.29 105
2019 Q1 104,271,703 $579,706,451 -$6,638,791 $5.56 112
2018 Q4 105,373,335 $699,630,313 -$17,077,199 $6.64 117
2018 Q3 107,498,975 $1,147,115,789 -$30,046,816 $10.67 114
2018 Q2 104,426,400 $1,253,163,056 -$371,540 $12.00 114
2018 Q1 109,754,416 $939,672,485 -$14,099,435 $8.57 118
2017 Q4 111,338,432 $1,100,040,141 -$44,224,810 $9.88 123
2017 Q3 110,485,325 $1,357,861,811 -$5,704,402 $12.29 130
2017 Q2 110,542,385 $1,818,248,643 +$18,151,870 $16.45 129
2017 Q1 109,854,396 $1,575,293,760 +$120,009,363 $14.34 130
2016 Q4 106,295,065 $1,470,204,819 -$2,532,260 $13.83 140
2016 Q3 106,140,794 $1,917,259,558 +$249,235 $18.07 138
2016 Q2 110,750,409 $1,589,249,524 +$1,094,261 $14.35 134
2016 Q1 110,808,225 $1,323,993,000 +$13,960,287 $11.95 126
2015 Q4 109,649,652 $1,459,682,001 +$54,951,710 $13.31 116
2015 Q3 105,860,530 $1,136,914,006 +$98,139,625 $10.74 99
2015 Q2 96,818,089 $779,385,263 +$779,385,260 $8.05 86